FOLH1 and prostate carcinoma: In solid tumors, ongoing studies include a pilot study of NKG2D ligand-targeted CAR-NK cells (NCT03415100), an early phase I study (NCT03692637) of anti-mesothelin CAR NK cells in patients with epithelial ovarian cancer, and an early phase I study (NCT03692663) of anti-Prostate Specific Membrane Antigen (anti-PSMA) CAR NK cells in patients with castration-resistant prostate cancer.